Diffuse Large B-Cell Lymphoma News

News

Axicabtagene Ciloleucel Significantly Improves Outcomes Over Standard Care as Second-Line Therapy for Large B-cell Lymphoma

05/13/2022

John Otrompke

Findings from the ZUMA-7 trial suggest axicabtagene ciloleucel is an effective alternative option for the second-line treatment of relapsed or refractory large B-cell lymphoma.

Findings from the ZUMA-7 trial...

05/13/2022

Oncology

News

Second-Line Tisagenlecleucel vs Standard Salvage Therapy for Aggressive B-cell Lymphoma

05/13/2022

John Otrompke

Second-line treatment with tisagenlecleucel was not superior to standard salvage therapy for patients with aggressive B-cell lymphoma, according to findings from the phase 3 BELINDA trial.

Second-line treatment with...

05/13/2022

Oncology

News

Polatuzumab Vedotin Improves PFS in Previously Untreated DLBCL

05/03/2022

John Otrompke

A modified regimen of R-CHOP in which vincristine is replaced with polatuzumab vedotin yielded lower risk of disease progression, relapse, or death among patients with previously untreated intermediate-risk or high-risk DLBCL.

A modified regimen of R-CHOP in...

05/03/2022

Oncology

News

Post-transplant Pembrolizumab May Delay Immune Reconstitution for Patients With DLBCL

04/07/2022

John Otrompke

Patients with DLBCL who received pembrolizumab as maintenance therapy following an autoHSCT experienced a delay of at least 18 months in the reconstitution of their CD19-positive cells, according to a flow cytometry study.

Patients with DLBCL who received...

04/07/2022

Oncology

News

FDA Approves Axicabtagene Ciloleucel for Relapsed or Refractory LBCL

04/04/2022

Emily Bader

The FDA approved axicabtagene ciloleucel for patients with LBCL that are refractory to or have relapsed within 12 months of first-line chemoimmunotherapy.

The FDA approved axicabtagene...

04/04/2022

Oncology

Conference Insider

Dr Leonard Highlights Crucial New Data, Practice Changing Therapies in DLBCL

03/23/2022

Alexa Stoia

John Leonard, MD, presents novel data with CAR-T therapies in upfront, second line DLBCL during the virtual Great Debates & Updates in Hematologic Malignancies.

John Leonard, MD, presents novel...

03/23/2022

Oncology

News

CAR T-Cell Therapy With TanCAR7 Demonstrates Efficacy in DLBCL

03/21/2022

John Otrompke

Some 70% of R/R NHL patients treated with tandem CD19/CD20 CAR T-cell therapy experienced a CR, findings from a single-arm phase 1/2 trial suggest.

Some 70% of R/R NHL patients...

03/21/2022

Oncology

News

Axicabtagene Ciloleucel Demonstrates Higher ORR in Japanese Patients With Relapsed or Refractory DLBCL

03/08/2022

John Otrompke

In a bridging study, the CAR T-cell therapy axicabtagene ciloleucel demonstrated efficacy in Japanese patients with R/R DLBCL. The ORR was 86.7%, which was even higher than it was in the pivotal ZUMA-1 study, which did not include any...

In a bridging study, the CAR...

03/08/2022

Oncology

News

Umbralisib Associated With a Better Safety Profile Than Other PI3K Inhibitors

03/01/2022

The use of single-agent umbralisib in adults with R/R NHL, including DLBCL, is associated with a favorable tolerability profile, including low rates of serious immune-mediated toxicities.

The use of single-agent...

03/01/2022

Oncology

News

Study Clarifies Superiority of High-Dose Methotrexate at EOI for High-Risk Patients With DLBCL

02/24/2022

A multicenter analysis has clarified the superiority of high-dose methotrexate at the EOI for high-risk patients with DLBCL.

A multicenter analysis has...

02/24/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology